Influence of chemotherapy on the biodistribution of [99mTc] hydrazinonicotinamide annexin V in cancer patients

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 53, Issue 2, 2009, Pages 127-132

  Rottey, S ^a   Van Den Bossche, B ^a   Slegers, G ^b   Van Belle, S ^a   Van De Wiele, C ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

Annexins; Drug therapy; Neoplasms; Technetium Tc 99m hydrazinonicotinamide annexin V

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; HYDRAZINONICOTINAMIDE TC 99M ANNEXIN V; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT; LIPOCORTIN 5; TECHNETIUM COMPLEX; TECHNETIUM TC 99M HYDRAZINONICOTINAMIDE ANNEXIN V; TECHNETIUM TC 99M HYDRAZINONICOTINAMIDE-ANNEXIN V;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; FEMALE; GEOMETRY; HEAD AND NECK CANCER; HEAD AND NECK CARCINOMA; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; LUNG SMALL CELL CANCER; MALE; NONPARAMETRIC TEST; OVARY CANCER; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; SCINTIGRAPHY; SQUAMOUS CELL CARCINOMA; TRANSITIONAL CELL CARCINOMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; METABOLISM; MIDDLE AGED; NEOPLASM; SCINTISCANNING; TIME; TISSUE DISTRIBUTION; WHOLE BODY IMAGING;

AGED; ANNEXIN A5; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; ORGANOTECHNETIUM COMPOUNDS; TIME FACTORS; TISSUE DISTRIBUTION; WHOLE BODY IMAGING;

EID: 69249213017     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Blankenberg F. To scan or not to scan, it is a question of timing: technetium-99m-Annexin V radionuclide imaging assessment of treatment efficacy after one course of chemotherapy. Clin Cancer Res 2002;8:2757-8. (Pubitemid 35025716)
2. 99mTc-annex V uptake and histologic findings in an experimental model. J Nucl Med 2004;45:2083-7.
3. 99mTc-Annexin V. J Nucl Med 2005;46:807-15. (Pubitemid 43750758)
4. 99mTc-hydrazinonicotinamide-annexin V imaging for predicting response to chemotherapy. J Nucl Med 2006;47: 1813-8.
5. Mandl SJ, Mari C, Edinger M, Negrin RS, Tait JF, Contag CH et al. Multi-modality imaging identifies key times for annexin V imaging as an early predictor of therapeutic outcome. Mol Imaging 2004;3: 1-8.
6. 99mTc-EC-annexin V. Cancer Biother Radiopharm 2001;16:73-83.
7. Belhocine T, Steinmetz N, Green A, Rigo P. In vivo imaging of chemotherapy-induced apoptosis in human cancers. Ann N Y Acad Sci 2003;1010:525-9.
8. Belhocine T, Steinmetz N, Hustinx R, Bartsch P, Jerusalem G, Seidel L et al. Increased uptake of the apoptosis-imaging agent (99m)Tc recombinant human Annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis. Clin Cancer Res 2002;8:2766-74.
9. Gardai SJ, Bratton DL, Ogden CA, Henson PM. Recognition ligands on apoptotic cells: a perspective. J Leukoc Biol 2006;79:896-903.
10. Gardai SJ, McPhillips KA, Frasch SC, Janssen WJ, Starefeldt A, Murphy-Ullrich JE et al. Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell 2005;123:321-34.
11. Brown S, Heinisch I, Ross E, Shawkely C, Savill J. Apoptosis disables CD31-mediated cell detachment from phagocytes promoting binding and engulfment. Nature 2002;418:200-3.
12. Kenis H, van Genderen H, Bennaghmouch A, Rinia HA, Frederik P, Narula J et al. Cell surface-expressed phosphatidylserine and annexin A5 open a novel portal of cell entry. J Biol Chem 2004;279:52623-9.
13. Kenis H, van Genderen H, Deckers NM, Lux PA, Hofstra L, Narula J et al. Annexin A5 inhibits engulfment through internalization of PS-expressing cell membrane patches. Exp Cell Res 2006;312: 719-26.
14. Berckmans R, Nieuwland R, Boing A, Romijn F, Hacke C, Sturk A. Cell-derived microparticles circulate in healthy humans and support low grade thrombin generation. Thromb Haemost 2001;85: 639-46. (Pubitemid 32293699)
15. Simák J, Holada K, Vostal JG. Release of annexin V-binding membrane microparticles from cultured human umbilical vein endothelial cells after treatment with camptothecin. BMC Cell Biol 2002;3:11.